
|Articles|December 16, 2016
ImmunoCellular Therapeutics Names New CEO
December 16, 2016
Advertisement
ImmunoCellular Therapeutics (Los Angeles, CA) announced that its Board of Directors has appointed Anthony Gringeri, Ph.D, as Chief Executive Officer. The appointment follows the decision by Andrew Gengos to resign the position of CEO. Mr. Gengos will continue to play an active role with the company as a member of the Board of Directors, the company reports. Dr. Gringeri has served as ImmunoCellular's Senior Vice President of Strategic Resources since August 2013. He joined ImmunoCellular from ViaCyte, where he was Vice President and Chief Development Officer. He previously served as Chief Operating Officer for Amsterdam Molecular Therapeutics.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Lipfendra to reduce LDL-C in Adults with Hypercholesterolemia
2
Jasper Therapeutics to Acquire Kira Pharmaceuticals in $132 Million Merger Agreement
3
Eli Lilly to Acquire AtaiBeckley for $2.8 Billion
4
Insilico Medicine Enters $2.5 Billion Alliance with Bora Pharmaceuticals
5




